Trials / Active Not Recruiting
Active Not RecruitingNCT05147558
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to find out whether biomarkers in the blood can predict the cancer's response to the study treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab (200mg every 3 weeks, intravenously) |
| DRUG | Lenvatinib | Lenvatinib (20mg once daily orally) |
Timeline
- Start date
- 2021-12-23
- Primary completion
- 2026-12-23
- Completion
- 2026-12-23
- First posted
- 2021-12-07
- Last updated
- 2026-02-27
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05147558. Inclusion in this directory is not an endorsement.